制药公司AstraZeneca原定于2026年11月1日停止向澳大利亚药品福利计划(PBS)供应月度Zoladex植入剂(3.6mg)，这一决定引发了乳腺癌和子宫内膜异位症患者的广泛担忧。[1]患者Ashleigh Middleton通过请愿书动员了公众力量，该请愿书获得超过42000人的签署。[1]面对舆论压力，AstraZeneca于2026年7月16日宣布逆转决定。[1]
根据新政策，符合条件且没有合适替代治疗方案的患者可通过Zoladex持续项目免费无限期获得该药物。[1]AstraZeneca发言人强调，"Zoladex持续项目不是有时间限制的项目"。[1]医学专家指出，月度高剂量(3.6mg)植入剂在激素抑制方面优于三个月一次的高剂量制剂(10.8mg)，对年轻女性尤其如此。[1]澳大利亚是全球唯一受原停供决定影响的市场。[1]截至2025年，共有13580名患者在使用该药物。[1]详细的患者注册和入群信息将于9月发布。[1]
Pharmaceutical company AstraZeneca has reversed its plan to discontinue supplying monthly Zoladex injections (3.6mg) to Australia's Pharmaceutical Benefits Scheme (PBS) starting November 2026.[1] On July 16, 2026, the company announced it would instead provide the medication free of charge indefinitely to patients without suitable alternative treatments.[1]
The reversal came after patient advocacy efforts gained significant traction. Ashleigh Middleton initiated a Change.org petition against the withdrawal, which garnered more than 42,000 signatures.[1] As of 2025, approximately 13,580 Australian patients were using the drug.[1] An AstraZeneca spokesperson confirmed the new arrangement, stating that "the Zoladex Continuity Program is not a time-limited program."[1]
Medical experts have noted that the monthly high-dose formulation (3.6mg) provides superior hormone suppression for younger women compared to the quarterly high-dose option (10.8mg).[1] Australia is the only global market affected by the original discontinuation decision.[1] Detailed enrollment procedures and program information are scheduled for release in September.[1]